Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 2/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24743012 | 0.91 | RORC (0.47) | HRH3RORCITGB3ITGA2BEGLN1 | |
| SCHEMBL6025250 | 0.84 | ADRB1 (0.46) | HRH3RORCITGB3ITGA2BEGLN1 | |
| SCHEMBL12342523 | 0.84 | HRH3 (0.45) | HRH3RORCITGB3ITGA2BEGLN1 | |
| SCHEMBL3127570 | 0.84 | USP2 (0.47) | HRH3RORCEGLN1PIM1 | |
| Hydrochloric Acid SCHEMBL2336913 | 0.83 | HRH3 (0.44) | HRH3RORCITGB3ITGA2BEGLN1 | |
| Hydrochloric Acid SCHEMBL2425459 | 0.83 | USP2 (0.46) | HRH3RORCEGLN1PIM1 | |
| SCHEMBL21764939 | 0.82 | USP2 (0.43) | HRH3RORCITGB3ITGA2BEGLN1 | |
| SCHEMBL17723583 | 0.81 | ADRB2 (0.46) | HRH3EGLN1PIM1 | |
| SCHEMBL2476740 | 0.81 | HRH3 (0.56) | HRH3ITGB3ITGA2BEGLN1LIPE | |
| SCHEMBL29348863 | 0.81 | HRH3 (0.43) | HRH3ITGB3ITGA2BEGLN1LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704121-B1 | DIAZASPIRO ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3704121-B1 | DIAZASPIRO ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11192891-B2 | Diazaspiro ROCK inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192891-B2 | Diazaspiro ROCK inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210188848-A1 | DIAZASPIRO ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188848-A1 | DIAZASPIRO ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3704121-A1 | DIAZASPIRO ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192891-B2 | Diazaspiro ROCK inhibitors | ROCK1, MYLK, ROCK2 | HRH3 2911/4885RORC 1788/4885ITGB3 2030/4885 |
| US-20210188848-A1 | DIAZASPIRO ROCK INHIBITORS | ROCK1, MYLK, ROCK2 | HRH3 2911/4885RORC 1788/4885ITGB3 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.